Onconetix, Inc.
NCM: ONCOLive Quote
📈 ZcoreAI Score
Our AI model analyzes Onconetix, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get ONCO Z-Score →About Onconetix, Inc.
Healthcare
Biotechnology
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.
📊 Fundamental Analysis
Onconetix, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported -57.4% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -115.5%, which indicates that capital utilization is currently under pressure.
At a current price of $1.09, ONCO currently trades near the bottom of its 52-week range (0%), indicating potential value or weakness (Range: $1.01 - $74.38).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$781,365
Trailing P/E
--
Forward P/E
-1.28
Beta (5Y)
3.63
52W High
$74.38
52W Low
$1.01
Avg Volume
5.58M
Day High
Day Low